Supplementary Materials

Figure S1





Figure S1. HCC1569 cells engineered to lack the expression of HER3 were generated by CRIPSR/Cas targeting of the HER3 gene. The effect of AIIB2 treatment on HCC1569 of wildtype and HER3 knockout genotypes was compared. The HER3 knockout cells have partially reduced growth, which is additive with AIIB2 treatment, and they have a compensatory increase in β1-integrin expression.

Figure S2



Figure S2. HCC1569 cells engineered to express a doxycycline-inducible HER3 shRNA or a scrambled control shRNA were treated with doxycycline for 72 hours and lysates were immunoblotted to confirm the knockdown of HER3 protein expression.

Figure S3



Figure S3. Simultaneous **k**nockdown of HER3 and intergrin B1 inhibition significantly reduces tumor growth in vivo. The on-treatment tumors were harvested at day 24, just prior to cessation of therapy. The post-treatment tumors for each group were harvested at the time of termination of that group.